2022
DOI: 10.1016/j.xhgg.2022.100132
|View full text |Cite
|
Sign up to set email alerts
|

Developmental genomics of limb malformations: Allelic series in association with gene dosage effects contribute to the clinical variability

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
2
2

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 98 publications
0
2
0
Order By: Relevance
“…Moreover, whole genome studies in the remaining “unsolved” MRKH probands may elucidate other genes and noncoding variants that may contribute to MRKH. Such studies may also further elucidate developmental genomics and inheritance models, such as the CIGD and Allele specific Gene Dosage (AsGD) models, 70 , 71 that underlie birth defects and enable more informative genetic counseling for families with children having rare birth defects.…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, whole genome studies in the remaining “unsolved” MRKH probands may elucidate other genes and noncoding variants that may contribute to MRKH. Such studies may also further elucidate developmental genomics and inheritance models, such as the CIGD and Allele specific Gene Dosage (AsGD) models, 70 , 71 that underlie birth defects and enable more informative genetic counseling for families with children having rare birth defects.…”
Section: Discussionmentioning
confidence: 99%
“…Learning such dose-response relationships from ‘experiments of nature’ has confirmed the role of PCSK9 in familial hypercholesterolaemia, LDL cholesterol, and coronary artery disease (as reviewed in [3]). More recently, Duan et al [4] described a naturally occurring allelic series in the BHLHA9 locus associated with the clinical severity and penetrance of congenital limb malformations. Allelic series can also be generated experimentally, as was done recently by Mohajeri et al [5], who used CRISPR to engineer an allelic series of MEF2C mutations in vitro , providing a cellular model for human neurodevelopmental disorders.…”
Section: Introductionmentioning
confidence: 99%